Aspire Biopharma Holdings (ASBP) Total Debt (2023 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Total Debt of $499214.0 for Q1 2026, little changed year-over-year from $499214.0 in Q1 2025, and down 82.11% quarter-over-quarter from $2.8 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Total Debt (2023 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Total Debt for 4 consecutive years, with $499214.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt changed 0.0% year-over-year to $499214.0; the TTM figure through Mar 2026 stood at $499214.0 (changed 0.0% YoY), while the FY2025 annual figure was $2.8 million, down 31.66% from the prior year.
- Total Debt fell to $499214.0 in Q1 2026 per ASBP's latest filing, from $2.8 million in the prior quarter.
- Across five years, Total Debt topped out at $5.3 million in Q3 2024 and bottomed at $24768.0 in Q4 2023.
- Historically, Total Debt has averaged $2.0 million across 4 years, with a median of $677395.0 in 2024.
- Annual changes were most pronounced in 2024 — Total Debt surged 16385.91% — and 2025, when it tumbled 41.65%.
- Aspire Biopharma Holdings' Total Debt stood at $24768.0 in 2023, then soared by 16385.91% to $4.1 million in 2024, then plunged by 31.66% to $2.8 million in 2025, then plunged by 82.11% to $499214.0 in 2026.
- Business Quant data shows ASBP's Total Debt at $499214.0 in Q1 2026, $2.8 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.34 Bn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 499,214.00 |
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 499,214.00 |
| Mar 31, 2025 | 499,214.00 |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 5.34 Mn |
| Jun 30, 2024 | 855,576.00 |
| Mar 31, 2024 | 434,464.00 |
| Dec 31, 2023 | 24,768.00 |